The Innovators Jam celebrates the extraordinary story of Jean Bennett, the scientist who turned gene therapy from science fiction into a miracle that gave children their sight back
Imagine growing up in a world that gets darker by every passing day.
Not metaphorically, but literally. You wake up one morning as a child and your vision is getting a little blurrier than yesterday. By your teenage, you can barely make out shapes in low light. By adulthood, you may be completely blind but there is nothing anyone can do about it.
This was the reality for thousands of people born with a condition called Leber Congenital Amaurosis (LCA). It is a rare inherited disease that destroys the light-sensing cells in the retina beginning in childhood. For most of medical history, LCA meant progressive blindness with no treatment, no cure, and no hope.
Then Jean Bennett came along and changed everything.
Who Is Jean Bennett?
Jean Bennett, Perelman School of Medicine Professor Emerita of Ophthalmology and former F.M. Kirby Professor of Ophthalmology, has spent more than three decades pushing the boundaries of what medicine thought was possible.
A physician-scientist and biomedical engineer at University of Pennsylvania and its Scheie Eye Institute, Bennett dedicated her career to finding cure for genetic diseases. She picked an ambitious goal to repair disease not by medicine or surgery, but rather by rewriting the faulty genes that cause it.
You won’t see her on magazine covers or trending on social media reels but her work in modern medicine touches the lives of millions across the globe. Her research and DNA rewriting technique changed the future of LCA blindness treatment.
On December 19, 2017, her therapy – called Luxturna – became the first FDA-approved gene therapy for an inherited disease in the United States. It was designed for patients with biallelic RPE65 mutation-associated retinal dystrophy. Her recommended treatment restored functional vision in children and adults who were otherwise expected to lose their sight.
It was a turning point not just for ophthalmology, but for the entire field of gene therapy. To understand its impact, we must first discuss gene therapy in detail and why for decades, many believed it was an impossible feat.
Explained: What Is Gene Therapy?
Every cell in our body contains DNA. This is a biological instruction manual that tells the body how to build, function and maintain itself. In some sense, it is like a software running and directing the hardware of body cells.
Sometimes, that software has a bug. A tiny error in the genetic code, called a mutation in biology, can cause a cell to malfunction. In the case of LCA, a mutation in a gene called RPE65 means the retinal cells cannot produce a protein they need to convert light into the electrical signals that the brain reads as vision. Without that protein, the cells slowly die. As a result, the vision slowly disappears.
Gene therapy is the idea that you can fix the mutation – not with a drug or a surgery, but by altering the correct copy of the faulty gene in the affected cells. If you can get the right genetic instructions into the right cells, the cells start producing the protein and vision can be restored.
In theory, it all sounded perfect. In practice, these experiments were a disaster for most of the 20th century.
The Long Road Nobody Wanted to Walk
Gene therapy’s history is marked with failures and long-awaited results. It is a long grind that people discuss but many never pursue.
In the 1990s, researchers were cautiously optimistic about gene therapy for LCA. Early trials showed promise. Then, in 1999, a young man named Jesse Gelsinger died during a gene therapy trial at the University of Pennsylvania. His death, possibly caused by a massive immune reaction to the viral vector used to deliver the gene, sent shockwaves through the scientific community. Clinical trials halted and funding dried up.
Most scientists quietly moved on. The stigma around gene therapy became stiff as many careers came to a halt. The public was sceptical and regulators became cautious.
But Jean Bennett did not move on. She had been working on retinal gene therapy since the early 1990s and she believed that a persistent approach was required to make it work.
The Experiment That Changed Everything
Bennett’s focus on the retina turned out to be strategically brilliant for many reasons. Most significantly, the eye has a property called ‘immune privilege’. Simply put, the immune system is less aggressive inside the eye than in most other parts of the body. This meant that the immune reaction that had killed Jesse Gelsinger was less likely to occur if the therapy was delivered directly into the retinal space. The eye provided a protected environment for testing the approach.
Working with her colleague Albert Maguire (who later became her husband), Bennett spent years refining a delivery mechanism using a modified virus called an adeno-associated virus, or AAV. The virus had been stripped of its disease-causing components and repurposed as a microscopic delivery vehicle carrying the correct RPE65 gene directly to the retinal cells that needed it.
The first human trial began in 2007. The initial patients were adults, chosen because the ethical risks of experimenting on children first were considered too high.
The results were cautiously positive. Their vision improved. There were no catastrophic immune reactions and the therapy appeared safe. Later they tried it on children.
The Moment Science Became a Miracle
The stories that emerged from the paediatric trials are the kind that make you stop and sit quietly for a moment. Children who had never been able to navigate a room without bumping into furniture could suddenly walk through obstacle courses.
Kids who had spent their lives terrified of the dark — because low-light environments were effectively invisible to them — could suddenly see in dim rooms. One child, after receiving the treatment, looked up at the stars for the first time.
For the families of these children, it was not a clinical trial result. It was a miracle.
Bennett has spoken publicly about the moment she realised the scale of what they had achieved. In interviews, she describes a quiet, almost disbelieving satisfaction — the kind that comes not from a single dramatic breakthrough, but from decades of unglamorous, painstaking work finally arriving somewhere extraordinary.
“We had to be very careful not to over-promise,” she has said. “But when you see a child navigate a maze in low light for the first time, you understand why you spent 25 years doing this,” she observed.
FDA Approval and the Birth of Luxturna
In December 2017, the FDA approved Luxturna — the brand name for the gene therapy Bennett helped develop — making it the first directly administered gene therapy approved in the United States for a genetic disease.
The approval was historic not just for what it was, but for what it represented. It proved that the approach worked. It demonstrated that a faulty gene could be identified, a correct version could be engineered, delivered safely to human cells, and produce a meaningful, lasting improvement in a patient’s life.
Luxturna is administered as a one-time injection beneath the retina of each eye. The procedure takes less than an hour. The effects, in many patients, are permanent.
The drug is manufactured by Spark Therapeutics, a company co-founded by Bennett and Maguire. At launch, it carried a list price of $425,000 per eye — making it, at the time, the most expensive drug in the United States. The price has been a subject of significant debate, raising difficult questions about who gets access to life-changing therapies and how medical innovation gets paid for. These are questions the field of gene therapy continues to wrestle with today.
Why Jean Bennett’s Work Matters Beyond One Disease
LCA affects roughly 1 in 80,000 people. In the grand scale of global disease burden, that is a small number. So why does Bennett’s work matter so enormously to scientists working on conditions that affect millions?
Because Luxturna was a proof of concept for the entire field.
Before 2017, gene therapy was still largely theoretical in the public imagination — a technology that sounded impressive in science magazines but had never actually delivered on its promise in the clinic. Luxturna changed that. It showed that the regulatory pathway existed, that the delivery mechanism worked, that the immune challenges could be managed, and that patients genuinely benefited.
In the years since the approval, the gene therapy pipeline has exploded. Therapies for sickle cell disease, haemophilia, muscular dystrophy, and dozens of other genetic conditions have moved into advanced clinical trials, many of them building directly on the framework that Bennett’s work helped establish. The FDA has approved several additional gene therapies since Luxturna, and analysts predict dozens more in the coming decade.
Jean Bennett opened a door that will let thousands of future patients walk through.
The Scientist Behind the Science
What makes Bennett’s story particularly compelling — and relevant to what we do at The Innovators Jam — is not just the science. It is the persistence.
She worked in a field that had been publicly humiliated. She continued at an institution still haunted by a tragedy connected to the very technique she was refining. She spent 25 years on a problem most of her peers had quietly abandoned. She did it methodically, carefully, and without the kind of public profile that attracts funding, fame, or institutional support.
This is what real innovation actually looks like. Jean Bennett’s name should be known by everyone. The fact that it isn’t is precisely why channels like this one exist.
The Innovators Jam Take
Gene therapy has been “the future of medicine” for thirty years. Jean Bennett is the reason it finally became the present.
What strikes us most about her story is not the Nobel-worthy science — though it is that. It is the timing. She chose to keep working on gene therapy at its lowest point, when the field had been publicly discredited and most of her colleagues had moved on. That decision, made quietly and without fanfare sometime in the early 2000s, is the reason children can see stars today.
The lesson for every founder, researcher, and builder reading this: the most important moment in innovation is rarely the breakthrough. It is the decision to keep going when everyone else has stopped.
Enjoyed this? Subscribe to The Innovators Jam for weekly spotlights on the scientists, founders, and disruptors changing our world.
Follow us on Instagram @theinnovatorsjam, Youtube @InnovatorsJam
Leave a Reply